The HumanFirst Institute has released an industry analysis highlighting the growing use of digital endpoints in pharmaceutical clinical trials.
The analysis reveals that over 130 pharmaceutical and biotech organisations have employed more than 1,300 AI-powered digital endpoints in their clinical trials. Key findings include that 60% of these endpoints are secondary, most trials deploying digital endpoints are in phase 2 or phase 4, and 10 therapeutic areas represent 82% of all pharma trials using digital endpoints.
This data underscores a significant increase in the adoption of digital endpoints in clinical trials, with recent regulatory guidance supporting the trend.
HumanFirst provides cloud-based technology for life sciences, offering insights on AI-powered biomarkers and clinical outcome assessments (COAs) to accelerate drug development and reduce costs.
Click here to read the original news story.